Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Capital Expenditures (2020 - 2023)

BioAtla (BCAB) has disclosed Capital Expenditures for 4 consecutive years, with $8000.0 as the latest value for Q4 2023.

  • For Q4 2023, Capital Expenditures fell 74.19% year-over-year to $8000.0; the TTM value through Sep 2024 reached $8000.0, down 93.39%, while the annual FY2023 figure was $98000.0, 63.43% down from the prior year.
  • Capital Expenditures hit $8000.0 in Q4 2023 for BioAtla, down from $25000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $662000.0 in Q2 2021 and bottomed at -$728000.0 in Q3 2021.
  • Average Capital Expenditures over 4 years is $59812.5, with a median of $28000.0 recorded in 2022.
  • On a YoY basis, Capital Expenditures climbed as much as 1059.42% in 2021 and fell as far as 746.51% in 2021.
  • BioAtla's Capital Expenditures stood at $590000.0 in 2020, then crashed by 101.19% to -$7000.0 in 2021, then soared by 542.86% to $31000.0 in 2022, then tumbled by 74.19% to $8000.0 in 2023.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $8000.0, $25000.0, and $15000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.